Chemotherapy of the Leukaemias.- The Use of Biological Response Modifiers in Acute Myeloid Leukaemia.- Biological Characteristics of Acute Myeloblastc Leukaemia Contributing to Management Strategy.- Bone Marrow Transplantation.- The Impact of Cytogenetics and Molecular Genetics on Diagnosis and Treatment.- Recent Advances in Chemotherapy for Certain Leukaemias.

The European School of Oncology came into existence to respond to a need for informa tion, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universi ties to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice.